In today’s competitive pharmaceutical landscape, speed and precision in regulatory filings can determine a product’s commercial success. At ResolveMass Laboratories […]
Case Study: How Our Analytical Development Laboratory Accelerated a Peptide NDA Filing Read More »
In the highly regulated pharmaceutical and chemical industries, regulatory compliance is not optional—it’s a legal, ethical, and scientific obligation. With
Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) has become a transformative tool in drug discovery and pharmaceutical analysis. Its precision,
Introduction Protein quantification is a foundational analytical requirement across life sciences, from early-stage research to regulated drug development. Organizations searching
How to Choose the Right Protein Quantification Lab in Montreal & Beyond Read More »
Introduction The presence of per- and polyfluoroalkyl substances (PFAS) in consumer products has become a critical concern in public health
Trace-Level PFAS Testing with LC-MS/MS: A Case Study on Consumer Product Packaging Read More »
Introduction: Why You Need the Right CRO for Unknown Impurity Identification In the pharmaceutical lifecycle, encountering an unexpected impurity—especially during
Best CRO Services for Identification of an Unknown Impurity in Canada and the U.S. Read More »
Introduction: Why Identification of an Unknown Impurity is Critical in Phase 3 Drug Development In late-stage pharmaceutical development, identification of
Introduction: The Role of Peptide Characterization in GLP-1 Analog Therapeutics In the development and QC stages of GLP-1 receptor agonists,
Peptide Characterization Case Study: Identifying Sequence Impurities in a GLP-1 Analog Read More »
Introduction: Why Addressing Leachables Risk in a Biologic Vial System is Crucial In 2025, the biopharmaceutical industry continues to face
E&L Testing CRO Case Study: Mitigating Leachables Risk in a Biologic Vial System Read More »
Introduction: Why Proactive Nitrosamine Testing is Critical in 2025 In 2025, regulatory scrutiny around nitrosamine contamination in pharmaceutical products continues
